Pancreatic enzyme replacement therapy for people with cystic fibrosis
Somaraju URR, Solis-Moya A
Published in Cochrane Database of Systematic Reviews
Methodology
Cochrane systematic review of randomised trials of pancreatic enzyme replacement therapy (PERT) in children and adults with cystic fibrosis
Key Findings
PERT formulations improved fat absorption versus placebo, but head-to-head comparisons between preparations were inconclusive
Conclusions
PERT is effective for exocrine pancreatic insufficiency in cystic fibrosis, though evidence comparing formulations and doses remains limited
Limitations
Small, short trials with heterogeneous outcome reporting
Supplements Studied
Most people with cystic fibrosis (CF) (80% to 90%) need pancreatic enzyme replacement therapy (PERT) to prevent malnutrition.
Outcomes Measured
Most people with cystic fibrosis (CF) (80% to 90%) need pancreatic enzyme replacement therapy (PERT) to prevent malnutrition.
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.